Apt3-4

Apt3-4 is a 2'-fluoro-modified RNA (2'-F-RNA) aptamer designed to target and inhibit Interleukin-17A (IL-17A), a pro-inflammatory cytokine central to the pathogenesis of autoimmune and inflammatory arthropathies. By binding specifically to IL-17A, Apt3-4 prevents the cytokine from interacting with its receptor (IL-17RA), thereby suppressing downstream signaling pathways that lead to the secretion of inflammatory mediators such as IL-6 and matrix metalloproteinase-13 (MMP-13). In preclinical in vitro models using peripheral blood mononuclear cells (PBMCs) and fibroblast-like synoviocytes (FLSs) from patients with axial spondyloarthritis and rheumatoid arthritis, Apt3-4 has demonstrated efficacy in suppressing IL-17A-induced inflammatory responses and cell proliferation. Its performance in these models has been shown to be comparable to the monoclonal antibody secukinumab, although its activity may diminish over longer durations compared to receptor-targeting agents. Apt3-4 represents a potential therapeutic alternative to monoclonal antibodies for IL-17-associated inflammatory conditions, offering advantages such as reduced immunogenicity and improved stability.